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Abstract Mesenchymal stem cells (MSC) have been used to
treat different clinical conditions although themechanisms by
which pathogenetic processes are affected are still poorly
understood.We have previously analyzed the homing of bone
marrow-derived MSC to diseased tissues characterized by a
high degree of mononuclear cell infiltration and postulated
that MSC might modulate inflammatory responses. Here, we
demonstrate that MSC mitigate adverse tissue remodeling,
improve organ function, and extend lifespan in amousemodel
of inflammatory dilative cardiomyopathy (DCM). Further-
more, MSC attenuate Lipopolysaccharide-induced acute lung
injury indicating a general role in the suppression of
inflammatory processes. We found that MSC released sTNF-
RI, which suppressed activation of the NFjBp65 pathway in
cardiomyocytes duringDCM in vivo. Substitution ofMSC by
recombinant soluble TNF-R partially recapitulated the bene-
ficial effects of MSC while knockdown of TNF-R prevented
MSC-mediated suppression of the NFjBp65 pathway and
improvement of tissue pathology. We conclude that sTNF-RI
is a major part of the paracrine machinery by which MSC
effect local inflammatory reactions.
Keywords Mesenchymal stem cells  Proteomics 
TNF-a  Fibrosis  Inflammation  Heart failure 
Acute lung injury
Introduction
Mesenchymal stem cells (MSC) are multipotent cells that
can be found in the stroma of various organs. MSC have
been originally described as adherent, non-hematopoietic
cells, which are present in the bone marrow of different
species (reviewed by [25]). Bone marrow-derived MSC
own a certain plasticity, which enables them to differenti-
ate into osteogenic, chondrogenic, and adipogenic lineages
[36]. Subsets of MSC have also been claimed to contribute
to various other cell types from all the three germ layers
including cardiomyocytes [14] but hard experimental evi-
dence for this hypothesis is limited [3, 25, 37].
Shortly after description of reliable methods to isolate
MSC clinical trials were launched to explore safety and
efficacy of MSC treatments. In hallmark studies it was
demonstrated that allogenic MSC have a potential to treat
children with osteogenesis imperfecta although further
studies indicated only a temporary short-term benefit (re-
viewed in [24]). Nevertheless, the concept that MSC might
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serve as a powerful ‘‘natural system for tissue repair’’
triggered the use of MSC as therapeutic agents in a variety
of experimental models of tissue injuries. Examples
include the treatment of chronic skin wounds, ischemic
hearts, damaged brains, lungs, kidneys, and other organs
(reviewed in [32]). In virtually all cases, the mechanism by
which MSC exerted positive effects remained enigmatic.
The finding, however, that the level of tissue engraftment
did not correlate with the therapeutic benefit suggested that
differentiation of MSC into functional parenchymal cells is
irrelevant in most settings [11, 15, 26, 28, 33]. Hence,
recent attention focused on the potential release of bioac-
tive factors by MSC, which might alter the tissue
microenvironment to stimulate organ-intrinsic progenitor
cells or modulate other pathogenetically relevant processes
such as inflammation (reviewed in [15, 25]). In fact, the
immunomodulatory effect of MSC has been already
described in initial transplantation experiments and there-
after found to be an active process based on the interaction
with T cells and other cells of the immune system such as
dendritic cells and macrophages (reviewed in
[5, 15, 25, 32]). Several factors have been identified, which
mediate these interactions in vitro but a thorough analysis
of the molecules that modulate immune responses and
inflammatory reactions in vivo proved to be difficult.
The tight regulation of pro- and anti-inflammatory pro-
cesses is particularly important during development of heart
failure and acute lung injury. It is assumed that the balance
between pro- and anti-inflammatory mediators regulates the
degree of the inflammatory response and thereby has amajor
impact on the course of the underlying disease [8, 13, 38].We
previously described that the cytokine receptor CCR2 is
necessary for organ-specific homing of adult bone marrow-
derived MSC to the heart in a transgenic mouse model of
inflammatory dilative cardiomyopathy and into hearts
damaged by ischemia/reperfusion. Both models are charac-
terized by a high degree of mononuclear cell infiltration and
inflammatory reactions,whichmight explainwhyMSCwere
efficiently attracted by a cytokine that is thought to be pri-
marily involved in the attraction of macrophages [4]. The
homing ofMSC into diseased organs characterized by strong
inflammatory reactions also raised the question whether
MSC modulate the disease process probably by exerting
immunosuppressive effects. We therefore started to explore
the potential beneficial effects of MSC in models of
inflammatory DCM and acute lung injury.
Here, we demonstrate that administration of MSC sig-
nificantly improved cardiac function and survival along
with an improvement of several morphological parameters.
Furthermore, MSC administration attenuated LPS-induced
lung injury suggesting that MSC provide beneficial effects
in different organs suffering from inflammatory processes.
To understand the molecular processes influenced by MSC,
we performed a comprehensive analysis of the secretome
of MSC and found that MSC release significant amounts of
sTNF-RI, which were sufficient to inhibit the NFjB sig-
naling pathway in vivo. Substitution of MSC by recombi-
nant soluble TNF-R partially recapitulated the positive
effects of MSC in the heart and lung indicating that release




Antibodies directed against soluble tumor necrosis factor
receptor I (sTNF-RI), lymphotoxin-a (LTa or TNFSF1)
were purchased from R&D systems. Antibodies recogniz-
ing phospho p65 (Ser536; P-p65), phospho IjBa (Ser32;
P-IjBa), and TNF receptor-associated factor 2 (Traf2)
were obtained from Cell Signaling Technology. Anti-fi-
bronectin, RalA (Ras-related protein) and pan-actin were
from Becton–Dickinson. Antibodies directed against acti-
nin and collagen VI were purchased from Sigma and
Biomol, respectively. Enbrel (Etanercept) and pentoxi-
fylline (PTX) were obtained from Amgen and Sanofi-
Aventis, respectively. The MIP-2a ELISA kit was pur-
chased from R&D systems.
shRNA-mediated knockdown of TNF-RI
The knockdown of TNF-RI was accomplished using the
MISSION shRNA system from Sigma–Aldrich. shRNA
lentiviral plasmids (in pLKO.1-puro) with the clone IDs
NM_011609.2-1538s1c1, NM_011609.2-996s1c1, and
NM_011609.2-1652s1c1 were employed to generate len-
tiviral particles, which were used to infect MSC
(MSC ? TRkd) as described previously [4]. The efficacy
of knockdowns was monitored by Western blot analysis
before intravenous injection into recipient mice. The non-
target shRNA control SHC002, which does not target a
mouse or human mRNA was used as a negative control.
Stem cell transplantation and drug treatment of wild
type and transgenic mice
The generation of MCP-1 transgenic mice on FVB/N
background, hereafter referred to as ‘‘TG’’, has been
described previously [16]. Wild type (WT) FVB/N mice
were used as control in morphological and Western blot
analyses. Housing and handling of mice were in accor-
dance with the American Physiological Society guidelines
for animal welfare and the Bioethical Committee of the
District of Darmstadt, Germany. Long-term renewing adult
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bone marrow-derived multipotent mesenchymal stem cells
(MSC) were isolated and transplanted into tail veins of
recipient hosts as described previously [4]. Treatment with
Enbrel was accomplished by subcutaneous injection at
10 lg/g body weight in saline solution while PTX was
injected intraperitoneally at 8 lg/g body weight in saline
solution. WT and TG mice were analyzed at 4 months of
age by MRI followed by the first injection of MSC, Enbrel
or PTX 2 weeks later. Injection of saline solution was used
as a sham control. Three additional injections of MSC,
Enbrel or PTX were done at weekly intervals as outlined in
(Fig. S1A). At 6 month of age, mice were analyzed by
MRI, western blot and immunofluorescence.
To induce acute lung injury, wild type mice C57/Bl6
mice were subjected to intratracheal instillation of 50 or
100 lg Lipopolysaccharide (LPS). Bronchoalveolar lavage
fluid (BALF) was collected at indicated time points.
Albumin leakage was determined as described previously
[12]. MSC, Enbrel and PTX were applied either intratra-
cheally (i.t.) or intraperitoneally (i.p.). Polymorphonuclear
leukocyte numbers were determined after Pappenheim
staining of cytospin preparations as described previously
[12].
Magnetic resonance imaging (MRI) studies
Cardiac MRI measurements were performed on a 7.0 T
Bruker Pharmascan, equipped with a 300 mT/m gradient
system, using a custom-built circularly polarized birdcage
resonator and the Early Access Package for self-gated
cardiac Imaging (Intragate, Bruker) [18]. MRI data were
analyzed using Qmass digital imaging software (Medis,
Leiden, Netherlands) as described previously [20].
Histology and immunofluorescence
Cryosections for histological and immunohistochemical
analyses were prepared from snap frozen hearts and sub-
jected to Masson’s trichrome according to the manufac-
turer’s instructions (Sigma–Aldrich). Immunofluorescence
was accomplished using 7 lm thick cryosections after 4 %
paraformaldehyde fixation for 10 min. After overnight
incubation with primary antibodies, slides were washed
with PBS and incubated with anti-rabbit Alexa 488- or
Alexa 594 -conjugated secondary antibodies (Alexa),
washed with PBS and counterstained with FITC- or
TRITC-conjugated phalloidin (Sigma) to visualize actin
[20]. Nuclei were visualized by incubation with DRAQ5TM
(Alexis biochemicals) for 15 min. Omission of the first
antibody served as negative control.
Mass spectrometry analysis
MSC were grown in SILAC medium for at least five cell
divisions as described previously to ensure complete
labeling of cells [17]. Cells were washed six times in
serum-free medium, and incubated in serum-free medium.
The conditioned medium containing the secreted proteins
was collected, filtered using a 0.45 lm filter (Millipore,
Bedford, MA) and concentrated using a 3000 Da molecular
mass cutoff spin column, Centriprep (Millipore). Process-
ing of protein samples and mass spectrometry was per-
formed as described [7] using an LTQ-Orbitrap (Thermo
Fisher Scientific) combined with an Agilent 1200 nanoflow
HPLC system. The mass spectrometer was operated in the
data-dependent mode to automatically measure full MS
scans and MS/MS spectra. Peptides were identified by
searching in the International Protein Index sequence
database (mouse IPI, version 3.24) using MaxQuant (ver-
sion 1.5.1.0), which performs peak lists, SILAC quantifi-
cation and false positive rate determination. Go-terms were
implemented using Perseus (version 1.5.0.15).
Preparation of protein extracts and Western blot
analysis
Protein extracts were prepared using standard procedures
[20]. Ten micrograms of protein extracts was separated on
4–12 % SDS–PAGE gradient gels and processed as pre-
viously described [40]. Immunoreactive proteins were
quantified with the Quantity One software (BioRad) after
visualization on the VersaDoc system (BioRad). Relative
concentrations of secreted cytokines were analyzed using
the RayBio cytokine antibody array 3.1 as described by the
supplier (RayBiotech, Norcross, USA).
Statistics
The following tests were used to investigate statistical
significance: (1) for three groups one-factor ANOVA and
subsequent Bonferroni multiple comparisons or Kruskal–
Wallis test and subsequent Dunn’s multiple comparisons in
the case of missing normality or heterogeneous variance of
the data; (2) for two groups unpaired t test or Mann–
Whitney U test in the case of missing normality or
heterogeneous variance of the data. For the survival anal-
ysis the Kaplan–Meier method was used. Differences in
survival between groups were tested using the log-rank test
and Pearson’s v2 test, respectively. p values less than 0.05
were considered statistically significant. No statistical
method was used to predetermine sample size.
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Results
MSC improve cardiac functions and extend
the lifespan of MyHC-MCP-1 transgenic mice
suffering from inflammatory dilative
cardiomyopathy
Intrigued by our previous observation that MSC efficiently
home into diseased hearts characterized by strong inflam-
matory reactions [4] we asked whether local accumulation
of MSC modulates inflammatory signaling processes in the
myocardium. We decided to focus our investigations on the
aMyHC-MCP-1 model. aMyHC-MCP-1 mice develop
inflammatory cardiomyopathy in a time dependent manner
[16] and attract MSC into the heart after intravenous
administration [4]. Cardiac functions of aMyHC-MCP-1
mice are still within the physiological range at 4 months
but deteriorate rapidly thereafter, leading to congestive
heart failure followed by premature death usually at
6 months [16, 34]. To test the ability of MSC to improve
the condition of aMyHC-MCP-1 mice, we performed four
weekly injections of MSC starting 2 weeks after an initial
assessment of the cardiac function by magnetic resonance
imaging (MRI) at 4 months of age (Fig. S1A). Two month
after initiation of the regimen cardiac functions the same
animals were analyzed again by MRI followed by mor-
phological and biochemical analyses. Sham-treated
aMyHC-MCP-1 mice (n = 5) showed left atrial (LA)
cavity dilatation (Fig. 1a, b), thrombus formation in the LA
(Figs. 1a, 2) and a decrease of the ejection fraction (EF)
from 54 % at 4 month to 32 % at 6 month (Fig. 1c). In
contrast, animals treated four times with 5.0 9 105 MSC
(n = 12) did not show a decline of ejection fractions as
determined by MRI (Fig. 1c). Moreover, dilation of the LA
and thrombus formation were significantly reduced in
treated compared to control animals (Figs. 1a, b, 2).
Importantly, we also observed a significant extension of the
lifespan of aMyHC-MCP-1 mice. All sham-treated animals
died before the age of 27 weeks whereas some MSC-
treated aMyHC-MCP-1 mice survived until the age of
36 weeks. The average lifespan increased from 24 ± 0.5
(untreated) to 28 ± 1.5 weeks (treated) (n = 8 for sham-
treated and n = 12 for MSC-treated mice, p\ 0.01)
(Fig. 1d).
Administration of MSC improves cardiac
morphology in a model of inflammatory dilative
cardiomyopathy
Next, we investigated the morphology of the myocardium
of aMyHC-MCP-1 mice at 6 month of age in MSC-treated
and control animals. Masson´s trichrome staining revealed a
diminished fibrosis in the LA and in the left ventricle (LV)
of MSC-treated mice (Fig. 2). Confocal imaging of sec-
tions stained with an antibody directed against collagen VI
indicated reduced collagen deposition and improved tissue
Fig. 1 Improvement of cardiac
function and lifespan extension
after injection of MSC into mice
with inflammatory DCM (TG).




Sham) or MSC injections
(TG ? MSC). The lack of
thrombus (T) formation in the
left atrium (LA) is clearly
visible. b Injection of MSC
prevented the decline in cardiac
performance and ventricular
dilatation of hearts of aMyHC-
MCP-1 mice. MRI images of
TG animals at 4 and 6 months
of age with and without
treatment are shown.
c Statistical evaluation of
improved ejection fraction at 4
and 6 months. d Survival curve
of aMyHC-MCP-1 mice (TG)
demonstrating significant
extension of the lifespan after
treatment with MSC
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architecture in treated aMyHC-MCP-1 mice, which went
along with reduced expression of ANP (Figs. 2, 3, S1B).
Both the LA and LV of treated aMyHC-MCP-1 mice were
characterized by moderately reduced infiltration with
CD45-positive inflammatory cells (Fig. S2).
Re-establishment and maintenance of blood supply are
of pivotal importance for damaged tissues. We therefore
investigated the distribution of capillary vessels in MSC-
treated and control mice. Staining with BS-1, a marker for
endothelial cells, revealed an increase of the capillary
density in the LA but not the LV of treated mice (n = 5 for
control, n = 12 for treated mice) (Figs. S3, S4). The
uneven increase of capillary density suggests that this
effect is most likely caused by indirect mechanisms and not
by differentiation of MSC to endothelial cells or direct
stimulation of endothelial cell growth since we did not find
a preferential accumulation of transplanted MSC within the
left atrium (data not shown).
MSC release a large number of biologically active
molecules
Our previous studies revealed that genetically labeled MSC
injected into aMyHC-MCP-1 mice either formed small
clusters or were scattered throughout the myocardium [4].
Careful morphological analysis indicated that virtually
none of these cells expressed cardiomyocyte markers such
as sarcomeric actinin and troponin, although a minor
fraction was positive for the endothelial cell marker BS-1
(Fig. S4 and data not shown). The relatively low number of
BS-1 positive cells suggested that most, if not all, of the
positive effects of MSC were mediated by the local release
of bioactive molecules. We therefore decided to investigate
the secretome of MSC using SILAC-based mass spec-
trometry. Culture supernatants were sampled at 4, 12, and
18 h resulting in identification of a total of 3066 proteins
with at least 2 peptides and 1 unique peptide (Table S1).
Next, we performed a Gene Ontology (GO)-annotation
analysis to identify proteins that were actively released
from MSC and not passively due to death of cells during
the sampling period. Based on the annotation we identified
585 proteins, which are localized at the plasma and base-
ment membrane, present in the cytosol, or secreted,
including several C–C– and C–X–C–motif chemokines,
SDF1 and SDF2, metalloproteinase inhibitors, and TNF-R
superfamily member 11B (Fig. S5; Table S1). Of these,
101 proteins were differentially enriched ([1.5-fold
change) in the secretome of MSC vs the mesenchymal cell
Fig. 2 Reduced cardiac fibrosis and thrombus formation after
intravenous injection of MSC into aMyHC-MCP-1 (TG) mice.
Masson’s trichromic and collagen VI staining of sections from left
atria and ventricles of TG mice, which received sham-treatment or
MSC injections. Sections from WT mice are shown for comparison.
Masson’s trichrome staining reveals reduced fibrosis in stem cell-
treated TG mice (TG ? MSC) in comparison to sham TG (TG-Sham)
and wild-type mice (WT). Collagen fibers (F) are stained blue and
muscle red. A large thrombus (T) is visible in sham-treated TG, which
is absent in stem cell-treated mice. Immunofluorescence images of
collagen VI demonstrate improved architecture of the extracellular
matrix and a reduced collagen deposition in stem cell-treated TG
mice. Scale bars 100 lm
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line 10T1/2 while the remaining 484 proteins were
expressed at similar or even higher levels by 10T1/2 cells.
Notably, six chemokine related proteins showed increased
secretion from MSC compared to 10T1/2 cells (Fig. S5;
Table. S1). Despite the excellent sensitivity of modern
mass spectrometry, it is still not possible to detect all low
abundant proteins. We therefore complemented our mass
spectrometry-based secretome measurements using protein
cytokine arrays. Analysis of conditioned cell culture
supernatants from MSC with the mouse cytokine array 3.1
(RayBiotech) that detects 62 cytokines validated the
release of 6 proteins (Axl, Cx3cl1, Igfbp5, Timp1, Vcam1,
Cxcl12) identified in the mass spectrometry experiment
(Table S1) and additionally recognized TARC/CCL17
(thymus- and activation-regulated chemokine) and sTNF-
RI (soluble TNF receptor I) (Fig. S5).
Heart failure in aMyHC-MCP-1 is associated
with activation of the TNF/NFjB signaling pathway
and downregulation of sTNF-RI
The improvement of cardiac functions of aMyHC-MCP-1
suffering from inflammatory DCM by MSC suggested that
MSC pathogenetically influence relevant processes in the
diseased heart probably by a mechanism that controls
inflammatory responses. Such postulate would also fit to
the proposed immunomodulatory function of MSC [5, 15].
One of the potentially most interesting molecules in this
respect is sTNF-RI, which was identified during our
secretome analysis of MSC (Fig. S5 and data not shown).
sTNF-RI is the soluble form of the receptor of tumor
necrosis factors, which is present at the surface of many
cells. sTNF-RI binds TNF-a and lymphotoxin-a (LTa or
TNFSF1) thereby inhibiting their activities, although it has
been shown that sTNF-RI also stabilizes TNF and increases
its half life under certain conditions [1, 2].
To investigate whether TNF-related processes are active
in aMyHC-MCP-1 mice, we analyzed several components
of the TNF-pathway by Western blot analysis. We detected
a strong expression of LTa in the LA and LV of aMyHC-
MCP-1 mice, which was completely absent in wild-type
control mice in the LA and LV (Fig. 3a, b). Interestingly,
we also found a significant downregulation of sTNF-RI,
which was strongly expressed in normal wild-type hearts
but was only faintly present in transgenic animals in the LA
and LV (Fig. 3a, b). Moreover, phosphorylation of
Fig. 3 Activation of the TNF-
signaling cascade in mice with
inflammatory dilated
cardiomyopathy. a Western blot
analyses of tissue lysates from
left atrium and left ventricle of
6-month-old wild-type (WT)
and aMyHC-MCP-1 mice (TG)
are shown. TG mice express
increased amounts of Collagen
VI (Col VI), phosphorylated-
p65 (Ser536; P-p65) and
lymphotoxin-a (LTa) in the
atrium and in the ventricle. The
expression level of sTNF-RI is
decreased in the atrium as well
in the ventricle of TG mice.
RalA (Ras-related protein)
served as loading control.
b Statistical analysis reveals
stronger effects in the atrium
compared to the ventricle of TG
mice
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NFjBp65, one of the main intracellular signal transducers
of TNF signaling, was strongly upregulated in the LA and
LV of transgenic mice indicating activation of the
inflammatory TNF-pathway (Fig. 3a, b). This observation
is consistent with the strong induction of the NFjBp65
targets Traf2 (TNF receptor-associated factor-2) and
fibronectin (Fig. S6A, B). Furthermore, we detected
increased phosphorylation of the NFjBp65 inhibitor IjBa
at S32, which leads to its proteasome-mediated degradation
causings derepression of NFjBp65 signaling (Fig. S8A, B).
Enhanced activation of inflammatory responses in trans-
genic animals went along with deposition of collagen VI in
the LA and LV corroborating our histological findings
(Fig. 2). Statistical analysis indicated that changes in the
activation of the TNF-pathway were more pronounced in
the atrium than in the ventricle (Fig. 3a, b).
Transplantation of MSC restores sTNF-RI
concentrations and inhibits NFjB activation
in the myocardium of aMyHC-MCP1 mice
We next examined whether transplantation of MSC affects
the TNF/NFjB system. Western blot analysis of the
myocardium of aMyHC-MCP1 mice, which received MSC
injections, showed a strong inhibition of phosphorylation
(activation) of NFjBp65 at Ser536 compared to sham-
treated controls (Fig. 4) (n = 3 for sham controls, n = 7
for treated mice, p\ 0.05). Similarly, treatment with
MSCs reduced levels of phosphorylated IjBa in aMHC-
MCP1 hearts, which prevents its degradation thereby
inhibiting NFjBp65 signaling. In addition, we observed
decreased expression of the NFjBp65 targets fibronectin
(Fn1) and Traf2 by immunofluorescence staining and
Western blot analysis (Fig. S8) which further corroborated
the inhibition of NFjBp65 signaling. Transplantation of
MSC also increased levels of sTNF-RI in the hearts of
aMyHC-MCP1 mice, which nearly reached levels seen in
wild-type controls (Fig. 4). Interestingly, the expression of
LTa dropped after transplantation of MSC (Fig. 4) sug-
gesting that MSC inhibited TNF-feedback loops, which are
believed to contribute to increased amounts of LTa in
inflamed organs [35]. The inhibition of NFjBp65 activa-
tion in MSC transplanted aMyHC-MCP1 mice was asso-
ciated with decreased deposition of collagen VI and
fibronectin (Fig. 4, S6). In contrast, MSC infected with a
lentivirus expressing a siRNA directed against TNF-RI
failed to block NFjBp65 activation, collagen VI deposi-
tion, LTa expression, and failed to restore sTNF-RI
expression (Fig. S7).
Recombinant soluble TNF receptor partially mimics
effects of MSC
The relation between sTNF-RI release byMSC, inhibition of
NFjBp65 activation, and inhibition of LTa expression in
hearts of aMyHC-MCP-1 mice strongly suggested that dis-
ruption of TNF signaling by sTNF-RI is at least partially
responsible for the positive effects of MSC on cardiac
function and survival. To prove this hypothesis we tried to
mimic the effects of MSC by administration of Enbrel (also
Fig. 4 Inhibition of TNF
signaling in hearts of aMyHC-
MCP-1 (TG) mice after
administration of MSC. Western
blot analyses of atria from
6-month-old transgenic animals
(TG), which received sham-
treatment or MSC injections.
Injection of MSC resulted in




increased levels of sTNF-RI.
RalA (Ras-related protein)
served as a loading control. The
statistical analysis of different
biological replicates is shown
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known as Etanercept), a recombinant protein that consists of
two extracellular domains of the TNF-RII receptor (p75)
fused to IgG1, and pentoxifylline (PTX), which increases the
intracellular concentration of cAMP cyclic adenosine
monophosphate resulting in decreased TNF-a production.
Treatment of aMyHC-MCP-1 mice with Enbrel led to sig-
nificant extension of the average lifespan from 25 weeks in
the sham-treated group to 34 weeks in the Enbrel group
(n = 12 control mice, n = 10 Enbrel-treated mice,
p\ 0.001) (Fig. 5a). In contrast, no extension of the lifespan
was monitored in the PTX group (n = 8 pentoxifylline-
treated mice) (Fig. 5a). aMyHC-MCP-1 mice treated with
either Enbrel or PTX showed a reduced degree of thrombus
formation andLAdilatation at 6 months of age, although this
effect was more pronounced in the Enbrel compared to the
PTXgroup (Fig. 5a).Masson’s trichrome staining revealed a
reduced fibrosis in the LA and LV (Fig. 5b) and a reduced
collagen deposition after both therapies (n = 13 for each
group). Similar to the LA and LV of MSC-treated mice
(Fig. S2), we also observed a reduced accumulation of
CD45-positive inflammatory cells in the LA and LV of
Enbrel- and PTX-treated animals (Fig. S8). Moreover, we
found an increase of the capillary density in the LA but not in
the LV of Enbrel-treated mice (Fig. S3). No increase in the
capillary density was detected in the PTX group (n = 13 for
each group) (Fig. S3). Surprisingly, assessment of cardiac
function by MRI did not reveal a consistent increase of the
ejection fraction in Enbrel- or PTX-treated animals com-
pared to the control group (data not shown).
To investigate whether improvement of cardiac mor-
phology and lifespan extension after Enbrel treatment was
associated with a reduced activation of the NFjB pathway,
we performed a Western blot analysis. We detected a
significant reduction of NFjBp65 phosphorylation in
Enbrel- and PTX-treated animals (n = 6, 5, 4 for Enbrel-
treated, PTX-treated, and sham-treated animals, respec-
tively, p\ 0.05), which was associated with reduced col-
lagen VI deposition and reduced concentrations of LTa
(Fig. 6a, b). Although treatment with Enbrel and PTX
mimicked several effects of transplanted MSC, we did not
observe an increase of sTNF-RI concentrations, which
might indicate that sTNF-RI was directly derived from
MSC. Taken together, our experiments revealed that
injection of recombinant soluble TNF receptor recapitu-
lated many, but not all effects of MSC suggesting that
inhibition of the TNF/NFjB pathway is responsible for a
major part of the beneficial effects of MSC in inflammatory
DCM.
Administration of MSC reduces LPS-induced
inflammatory lung injury
TNF signaling also plays a major role in the pathophysi-
ology of lung diseases such as acute lung injury (ALI) and
Fig. 5 Administration of
recombinant soluble TNF
receptor (Enbrel) mimics effects
of MSC in aMyHC-MCP-1
mice. a Macroscopic views of
hearts dissected from aMyHC-
MCP-1 mice (TG) after Enbrel,
Pentoxifylline (PTX), or sham-
treatment at 6 months of age.
Treatment with Enbrel reduced
atrial and ventricular dilatation
and prevented thrombus
formation. Statistical analysis of
the survival time of TG mice
after treatment with Enbrel and
Pentoxifylline is shown on the
right. b Masson’s trichrome
staining shows reduced fibrosis
in the left atrium and left
ventricle of Enbrel- or PTX-
treated animals. Collagen fibers
are stained blue and muscle is
red. Scale bars 100 lm
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chronic obstructive pulmonary disease (reviewed by [27]).
To determine whether the release of sTNF-RI by MSC
represents a general principle that might explain the ben-
eficial role of MSC in the suppression of inflammatory
processes, we induced ALI through intratracheal adminis-
tration of the bacterial endotoxin Lipopolysaccharide
(LPS). In agreement with previous findings we detected a
more than 20-fold increase of TNF-a concentrations by
ELISA in the bronchoalveolar lavage fluid (BALF) within
6 h after intratracheal instillation of 50 lg LPS compared
to sham-treated controls (Fig. 7a). Furthermore, we
observed a robust recruitment of polymorphonuclear
leukocytes (PMN) (Fig. 7c) into the alveolar space at 6 and
24 h after LPS administration, which was accompanied by
leakage of FITC-labeled albumin from the vascular into the
alveolar compartment, indicative of barrier function loss
[12] (Fig. 7b). The damage of the alveolar epithelial barrier
was also reflected by the presence of numerous erythro-
cytes in the BALF (Fig. 7e). Importantly, intratracheal
instillation of 5 9 105 MSC improved LPS-induced alve-
olar epithelial barrier leakage and reduced accumulation of
PMN and the concentration of macrophage inflammatory
protein 2a (MIP-2a), a PMN recruiting cytokine, in the
BALF (Fig. 7b, c). In contrast, administration of MSC, in
which the TNF-RI was knocked down by shRNA
(MSC ? TRkd), did not correct any parameters of ALI.
The number of PMN (3.1 9 106 PMN in MSC-treated
animals vs 4.4 9 106 PMN in MSC ? TRkd, p\ 0.05) as
well as alveolar leakage (0.05 AU in MSC-treated mice vs
0.09 AU in MSC ? TRkd treated animals; p\ 0.05) did
not show any significant differences compared to sham-
treated mice (Fig. 7b, c). Similarly, the concentration of
MIP-2a did not decline in the BALF of mice that received
MSC ? TRkd (Fig. 7c). To further prove that sTNF-RI is a
major mediator of the positive effects of MSC during ALI,
we administered Enbrel instead of MSC releasing sTNF-
RI. We found that Enbrel recapitulated most effects of
MSC in mice with ALI including reduction of albumin
leakage, reduction of PMN numbers, and decrease of MIP-
2a in the BALF (Fig. 7c, d). We noted that it was more
effective to administer Enbrel i.t. rather than i.p., which
might be explained by a better bioavailability of the protein
within the damaged tissue (Fig. 7d). Taken together, our
data strongly suggest that MSC exert protective effects in
different inflammatory conditions by release of sTNF-RI.
Discussion
Transplantations of MSC are used in numerous preclinical
and clinical studies to enhance repair of damaged tissue
and to attenuate immunological dysfunctions. In a recent
review 344 registered clinical trials were counted that are
designed to evaluate MSC therapy for multiple diseases
[41]. Yet, the mechanisms behind clinical benefits are still
mostly enigmatic. Initially, the therapeutic concept for
treatment was based on the assumption that MSC differ-
entiate and replace damaged tissue (see for example [30]
and [29]). This view has changed to implement findings
that MSC or their progenies do neither engraft nor differ-
entiate efficiently within host tissues but nevertheless
induce clear effects (see [11] for an example). Nowadays,
most researchers favor the view that MSC act via different
paracrine mechanisms [21] or exert immunomodulatory
activities [5, 15]. Similarly, we did not find convincing
evidence for differentiation of MSC into parenchymal cells
when we traced the fate of injected cells during the course
of our study, emphasizing the concept of paracrine sig-
naling as the main basis for effects of MSC.
Fig. 6 Administration of recombinant soluble TNF receptor (Enbrel)
mimics several biochemical effects of MSC in aMyHC-MCP-1 mice.
a Western blot analyses of tissue lysates from the left atrium of
6-month-old aMyHC-MCP-1 mice (TG) after Enbrel (TG ? Enbrel),
Pentoxifylline (TG ? PTX), or sham-treatment (TG-Sham) are
shown. Treatment with Enbrel or PTX decreased expression of
collagen VI (Col VI) and LTa and resulted in reduced phosphory-
lation of NFjBp65 (Ser536; P-p65). Please note that treatment with
Enbrel (unlike treatment with MSC) does not result in increased
expression of sTNF-RI while treatment with PTX resulted in a further
(non-significant) reduction of sTNF-RI levels. RalA (Ras-related
protein) served as a loading control. b Statistical analysis of Western
blots shown in (a)
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We have previously described that subsets of MSC rely
on the cytokine receptor CCR2 and its intracellular
receptor FROUNT for accumulation in hearts damaged by
inflammation or ischemia/reperfusion [3, 4]. Here, we
demonstrate that administration of MSC improves cardiac
morphology/function and extends the lifespan of mice
suffering from inflammatory cardiomyopathy. Similarly,
MSC alleviated several signs of ALI suggesting that mul-
tiple inflammatory conditions can be targeted by MSC
treatment. Analysis of the secretome of MSC revealed that
MSC release sTNF-RI, thereby, blocking a major inflam-
matory pathway. We reason that this mechanism is
responsible for the beneficial effects of MSC in inflam-
matory cardiomyopathy and ALI based on three argu-
ments: (1) administration of MSC restored sTNF-RI
concentrations, reduced the amount of LTa, and inhibited
activation of NFjBp65 in the heart, which all can be
explained by inhibition of TNF-R signaling. (2)
Fig. 7 Attenuation of LPS-
induced ALI after
administration of MSC or
Enbrel. a Time course of TNF-a
concentrations in the
bronchoalveolar lavage fluid
(BALF) of mice after
intratracheal instillation of LPS.
b Intratracheal administration of
MSC reduced alveolar leakage
in LPS-induced ALI. MSC in
which sTNF-RI was knocked
down (MSC ? TRkd) did not
show significant effects
compared to sham-treated
animals. c Administration of
WT MSC or Enbrel but not
MSC ? TRkd reduced the
concentration of MIP-2a and
the number of
polymorphonuclear cells (PMN,
mainly neutrophils) in the
BALF. d Intratracheal
instillation (i.t.) but not
intraperitoneal injection (i.p.) of
Enbrel reduced albumin leakage
and accumulation of PMN in the
BALF during LPS-induced ALI.
e Pappenheim staining of
cytospin preparations from the
BALF of mice with LPS-
induced ALI after
administration of wild-type
MSC or MSC ? TRkd.
Treatment with WT MSC but
not MSC ? TRkd reduced
alveolar PMN accumulation and
improved the barrier function as
indicated by reduced alveolar
hemorrhage
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Replacement of MSC by recombinant sTNF-R recapitu-
lated most of the effects of MSC in inflammatory car-
diomyopathy and ALI. (3) Knockdown of sTNF-RI in
MSC resulted in the failure of MSC to inhibit TNF-R
signaling and abrogated beneficial effects. Despite this
accumulated evidence, we do not claim that all effects of
MSC can be explained solely by the release of sTNF-RI, in
particular since MSC secrete a large variety of additional
bioactive molecules such as cytokines, thrombospondins,
matrix metalloproteinase inhibitors, IGF-binding proteins,
and SDF-1, which might contribute to the observed effects
of MSC. In this context, it is interesting to note that
treatment with Enbrel improved cardiac morphology and
extended the lifespan but did not improve the cardiac
ejection fraction. This observation might suggest the
involvement of additional factors released by MSC but also
indicates that the increased ejection fraction after admin-
istration of MSC is not instrumental for the survival of the
animals.
Since both inflammatory monocytes/macrophages and
MSC express CCR2, it is tempting to speculate that the
release of CCL2 in damaged tissue will summon both
inflammatory cells as well as MSC, which might counteract
excessive inflammatory responses. Interestingly, we found
significant concentrations of sTNF-RI in healthy hearts,
although we do not know the relative contribution from
circulating or tissue-resident MSC and other cell types.
Such local levels of sTNF-RI might act as a safeguard to
restrict TNF signaling in healthy hearts. We detected a
significant drop of sTNF-RI concentrations during the
course of inflammation, which was normalized by admin-
istration of MSC thereby partially restoring a potential
countermeasure. Since MSC release sTNF-RI, it seems
reasonable to assume that increased levels of sTNF-RI
directly originate from recruited MSC although we cannot
exclude a more indirect effect. Increased concentrations of
sTNF-RI might affect both TNF-a and LTa. So far, it was
assumed that TNF-a is the dominant ligand for TNF
receptors in inflammatory cardiomyopathy [23]. Hence, the
marked increase of LTa in the LV and even more pro-
nounced in the LA was surprising. LTa is a rare cytokine,
which is expressed by activated T cells, B cells, natural
killer cells, and some non-hematopoietic cells while TNF-a
is derived from invading monocytes/macrophages and from
many resident cardiac cell types. On the other hand, TNF-a
and LTa bind to the same receptors [p55 (TNF-RI) and p75
(TNF-RII)], which are present on almost every cell type in
the cardiovascular system, and elicit a similar spectrum of
activities [6]. Since TNF-a causes an increase of LTa
expression in inflamed organs probably by promoting
T-cell infiltration [35], the suppression of LTa expression
by administration of MSC might reflect a general inhibition
of inflammatory responses. This conclusion would also fit
well to the reduced presence of inflammatory cells and the
improved cardiac morphology in MSC-treated hearts. In
addition, a part of the beneficial effects of MSCs on the
myocardium of aMyHC-MCP-1 mice, which is character-
ized by reduced capillary density, might be due to pro-
angiogenic activities of MSC. In fact, MSCs have been
claimed to support angiogenesis either by enhancing
endothelial cell growth and survival [39] or by differenti-
ation into endothelial cells [31], although we did not obtain
clear evidence for a significant contribution of transplanted
MSC to endothelial cells in our experiments.
A link between TNF-signaling and chronic heart failure
has been proposed some time ago [19], although it took a
while to translate these findings into a clinical application.
Initially, treatment of chronic heart failure with Enbrel was
described to exert beneficial effects [9, 10] but a large
randomized trial (‘‘RECOVER’’ and ‘‘RENAISSANCE’’)
was stopped because primary endpoint results yielded no
positive effects [22]. In contrast to our well-defined pre-
clinical animal model of inflammatory DCM, human
patients participated in the clinical study, who developed
chronic heart failure due to a wide spectrum of different
etiologies. Other major differences were the inclusion of
patients with different degrees of chronic heart failure
(NYHA class II–IV) and the premedication of human
patients with a number of different drugs [22]. Our animal
data suggest that patients suffering from inflammatory
DCM might benefit from the treatment with MSC or Enbrel
and that it is instrumental to initiate the treatment at early
disease stages before severe damages have accumulated. In
our comparative study, the use of MSC was superior to the
treatment with Enbrel and PTX in respect to tissue mor-
phology and heart function. Two reasons might account for
these differences: (1) MSC release numerous different
factors that might act together with sTNF-RI and increase
its effectiveness. (2) MSC accumulate within diseased
regions of the heart which will increase local concentra-
tions of sTNF-RI and reduce systemic side effects.
Taken together we have demonstrated that administra-
tion of MSC suppressed inflammatory processes in the
heart and in the lung most likely by inhibition of NFjBp65
signaling via sTNF-RI. In both tissues, disease parameters
were improved by treatment with MSC including extended
survival of mice suffering from inflammatory DCM. It
seems likely that improved homing of MSC coupled with
enhanced release of sTNF-RI or similar molecules will
further increase treatment efficiency. We reason that the
usage of MSC with anti-inflammatory properties presents
an attractive approach to treat human patients suffering
from chronic inflammatory heart and lung diseases.
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